Abstract
Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). Objective: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy,in relieving behavioral and psychological symptoms of dementia (BPSD). Methods: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. Results: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress. Conclusion: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 15-19 |
| Number of pages | 5 |
| Journal | Journal of Alzheimer's Disease |
| Volume | 51 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 27 2016 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alzheimer's disease
- behavioral and psychological symptoms of dementia
- cannabis
- tetrahydrocannabinol
ASJC Scopus subject areas
- General Neuroscience
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health
Fingerprint
Dive into the research topics of 'Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS